Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]R. Krumlauf: Hox genes in vertebrate development. Cell, 78(2), 191-201 (1994)

  • [2]S. D. Hueber and I. Lohmann: Shaping segments: Hox gene function in the genomic age. BioEssays, 30(10), 965-979 (2008)

  • [3]P. Dollé, J. C. Izpisúa-Belmonte, J. M. Brown, C. Tickle and D. Duboule: HOX-4 genes and the morphogenesis of mammalian genitalia. Genes & Development, 5(10), 1767-1776 (1991)

  • [4]Yokouchi Y, Sasaki H and K. A: Homeobox gene expression correlated with the bifurcation process of limb cartilage development. Nature, 353(6343), 3 (1991)

  • [5]J. Miao, Z. Wang, H. Provencher, B. Muir, S. Dahiya, E. Carney, C.-O. Leong, D. C. Sgroi and S. Orsulic: HOXB13 promotes ovarian cancer progression. Proceedings of the National Academy of Sciences, 104(43), 17093-17098 (2007)

  • [6]B. A. T. Rodriguez, A. S. L. Cheng, P. S. Yan, D. Potter, F. J. Agosto-Perez, C. L. Shapiro and T. H.-M. Huang: Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis, 29(7), 1459-1465 (2008)

  • [7]Okuda H, Toyota M, Ishida W, Furihata M, Tsuchiya M, Kamada M, Tokino T and S. T: Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene, 25(12), 10 (2005)

  • [8]Zhao Y, Yamashita T and I. M.: Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep., 13(4), 6 (2005)

  • [9]Y.-R. Kim, K.-J. Oh, R.-Y. Park, N. Xuan, T.-W. Kang, D.-D. Kwon, C. Choi, M. Kim, K. Nam, K. Ahn and C. Jung: HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Molecular Cancer, 9(1), 124 (2010)

  • [10]L. Zeltser, C. Desplan and N. Heintz: Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development, 122(8), 2475-2484 (1996)

  • [11]T. Sreenath, A. Orosz, K. Fujita and C. J. Bieberich: Androgen-independent expression of hoxb-13 in the mouse prostate. The Prostate, 41(3), 203-207 (1999)

  • [12]K. D. Economides and M. R. Capecchi: Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development, 130(10), 2061-2069 (2003)

  • [13]Huang L, Pu Y, Hepps D, Danielpour D and P. GS: Posterior Hox Gene Expression and Differential Androgen Regulation in the Developing and Adult Rat Prostate Lobes. Endocrinology, 148(3), 1235-1245 (2007)

  • [14]J. D. Norris, C.-Y. Chang, B. M. Wittmann, R. S. Kunder, H. Cui, D. Fan, J. D. Joseph and D. P. McDonnell: The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens. Molecular Cell, 36(3), 405-416 (2009)

  • [15]S. Chauvet, S. Merabet, D. Bilder, M. P. Scott, J. Pradel and Y. Graba: Distinct Hox protein sequences determine specificity in different tissues. Proceedings of the National Academy of Sciences, 97(8), 4064-4069 (2000)

  • [16]F. Chen and M. R. Capecchi: Paralogous mouse Hox genes, Hoxa9, Hoxb9, and Hoxd9, function together to control development of the mammary gland in response to pregnancy. Proceedings of the National Academy of Sciences, 96(2), 541-546 (1999)

  • [17]A. Garcia-Gasca and D. D. Spyropoulos: Differential mammary morphogenesis along the anteroposterior axis in Hoxc6 gene targeted mice. Developmental Dynamics, 219(2), 261-276 (2000)

  • [18]C. A. Podlasek, J. Q. Clemens and W. Bushman: HOXA-13 gene mutation results in abnormal seminal vesicle and prostate development. The Journal of Urology, 161(5), 1655-1661 (1999)

  • [19]C. A. Podlasek, D. Duboule and W. Bushman: Male accessory sex organ morphogenesis is altered by loss of function of Hoxd-13. Developmental Dynamics, 208(4), 454-465 (1997)

  • [20]C. A. Podlasek, R. M. Seo, J. Q. Clemens, L. Ma, R. L. Maas and W. Bwushman: Hoxa-10 deficient male mice exhibit abnormal development of the accessory sex organs. Developmental Dynamics, 214(1), 1-12 (1999)

  • [21]X. Warot, C. Fromental-Ramain, V. Fraulob, P. Chambon and P. Dolle: Gene dosage-dependent effects of the Hoxa-13 and Hoxd-13 mutations on morphogenesis of the terminal parts of the digestive and urogenital tracts. Development, 124(23), 4781-4791 (1997)

  • [22]C. J. Bieberich, K. Fujita, W.-W. He and G. Jay: Prostate-specific and Androgen-dependent Expression of a Novel Homeobox Gene. Journal of Biological Chemistry, 271(50), 31779-31782 (1996)

  • [23]P. J. Sciavolino, E. W. Abrams, L. Yang, L. P. Austenberg, M. M. Shen and C. Abate-Shen: Tissue-specific expression of murine Nkx3.1. in the male urogenital system. Developmental Dynamics, 209(1), 127-138 (1997)

  • [24]R. P. McMullin, A. Dobi, L. N. Mutton, A. Orosz, S. Maheshwari, C. S. Shashikant and C. J. Bieberich: A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland. Proceedings of the National Academy of Sciences, 107(1), 98-103 (2010)

  • [25]Stelnicki EJ, Arbeit J, Cass DL, Saner C, Harrison M and L. C.: Modulation of the human homeobox genes PRX-2 and HOXB13 in scarless fetal wounds. J Invest Dermatol, 111(1), 7 (1998)

  • [26]L. G. Kömüves, X.-K. Ma, E. Stelnicki, S. Rozenfeld, Y. Oda and C. Largman: HOXB13 homeodomain protein is cytoplasmic throughout fetal skin development. Developmental Dynamics, 227(2), 192-202 (2003)

  • [27]J. A. Mack, L. Li, N. Sato, V. C. Hascall and E. V. Maytin: Hoxb13 Up-regulates Transglutaminase Activity and Drives Terminal Differentiation in an Epidermal Organotypic Model. Journal of Biological Chemistry, 280(33), 29904-29911 (2005)

  • [28]N. Chung, B. Jee, S. Chae, Y.-W. Jeon, K. Lee and H. Rha: HOX gene analysis of endothelial cell differentiation in human bone marrow-derived mesenchymal stem cells. Molecular Biology Reports, 36(2), 227-235 (2009)

  • [29]Bray F, Ren JS, Masuyer E and F. J: Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer, 132(5), 12 (2013)

  • [30]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and F. Bray: GLOBOCAN 2012 v1.0., Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 (Internet) In: Lyon, France: International Agency for Research on Cancer, (2013)

  • [31]Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and T. MJ.: Cancer statistics, 2005. CA Cancer J Clin., 55(1), 30 (2005)

  • [32]Waleed A. Hassen, Farrok A. Karsan, Farhat Abbas, Yasar Beduk, Ahmed El-Khodary, Marwan Ghosn, Jamal Khader, Raja Khauli, Danny M. Rabah, Ali Shamseddine and S. Srinivas: Modification and Implementation of NCCN Guidelines™ on Prostate Cancer in the Middle East and North Africa Region. J Natl Compr Canc Netw 8, 3 (2010)

  • [33]S. P. Balk: Androgen receptor as a target in androgen-independent prostate cancer. Urology, 60(3, Supplement 1), 132-138 (2002)

  • [34]B. J. Feldman and D. Feldman: The development of androgen-independent prostate cancer. Nat Rev Cancer, 1(1), 12 (2001)

  • [35]D. B. Agus, C. Cordon-Cardo, W. Fox, M. Drobnjak, A. Koff, D. W. Golde and H. I. Scher: Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen Independence. Journal of the National Cancer Institute, 91(21), 1869-1876 (1999)

  • [36]Denmeade SR, Lin XS and I. JT.: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28(4), 15 (1996)

  • [37]Leewansangtong S, Soontrapa S and T. A.: Is prostate-specific antigen still the best tumor marker for prostate cancer? J Med Assoc Thai., 82(10), 7 (1999)

  • [38]C. Jung, R.-S. Kim, H.-J. Zhang, S.-J. Lee and M.-H. Jeng: HOXB13 Induces Growth Suppression of Prostate Cancer Cells as a Repressor of Hormone-Activated Androgen Receptor Signaling. Cancer Research, 64(24), 9185-9192 (2004).

  • [39]J. P. Breyer, T. G. Avritt, K. M. McReynolds, W. D. Dupont and J. R. Smith: Confirmation of the HOXB13 G84E Germline Mutation in Familial Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention, 21(8), 1348-1353 (2012)

  • [40]V. Muthusamy, S. Duraisamy, C. M. Bradbury, C. Hobbs, D. P. Curley, B. Nelson and M. Bosenberg: Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma. Cancer Research, 66(23), 11187-11193 (2006) 41. P.-L. Jerevall, A. Jansson, T. Fornander, L. Skoog, B. Nordenskjold and O. Stal: Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Research, 12(4), R53 (2010)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

Hoxb13, a potential prognostic biomarker for prostate cancer

Allal Ouhtit 1,*, Mohammed N Al-Kindi 2, Parvathy R Kumar 1, Ishita Gupta 1, Somya Shanmuganathan 1, Yahya Tamimi 2
Affiliations
Article Info

1 Department of Genetics, Sultan Qaboos University, PO Box 35, PC 123, Al Khoud, Sultanate of Oman

2 Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, PO Box 35, PC 123, Al Khoud, Sultanate of Oman

*Author to whom correspondence should be addressed.

 

Abstract

HOXB13, a member of the homeobox proteins family, is a key regulator of the epithelial differentiation in the prostate gland. HOXB13 is overexpressed during malignant progression of the prostatic tissue and suspected to contribute in the pathogenesis of the prostate gland. In androgen deprived conditions, HOXB13 is thought to act through inhibition of the tumour suppressor protein p21. Since HOXB13 has a multifaceted role in ventral prostate development, its critical partners in the cascade need to be elucidated for a further understanding of its role in prostate malignancy. In this report, we review the functions attributed to HOXB13, by highlighting the most recent findings supporting the hypothesis that HOXB13 might serve as a novel biomarker for the prognosis of prostate cancer.

Keywords

  • HOXB13
  • prostate cancer
  • Androgen
  • Review

References